AptarGroup, Inc.
HealthcareNYSE:ATR · New York Stock Exchange
+$1.14 today
Vol 0.26M · Avg 0.52M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $392.8M +5.0% | $374.2M +31.7% | $284.2M +18.6% | $239.6M -1.7% | $243.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $287.4M +8.9% | $263.8M +6.1% | $248.6M +6.4% | $233.7M -0.5% | $234.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$11.7M +45.4% | -$21.4M -7.7% | -$19.9M -64.2% | -$12.1M +15.7% | -$14.4M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $47.6M +15.4% | $41.3M +0.9% | $40.9M +5.3% | $38.9M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$125.4M -288.9% | -$32.3M -660.9% | $5.8M +112.8% | -$45.0M +73.5% | -$169.7M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$73.9M -308.7% | -$18.1M -217.2% | $15.4M +155.2% | -$27.9M +77.3% | -$123.3M | $592.6M | $1.3B | $626.2M |
| Inventory | -$10.6M -148.6% | $21.9M +305.8% | -$10.6M +82.4% | -$60.4M +24.5% | -$80.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$18.3M +22.9% | -$23.7M -262.4% | $14.6M -73.5% | $55.1M +5.3% | $52.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$22.6M -82.9% | -$12.4M +9.2% | -$13.6M -15.5% | -$11.8M +37.2% | -$18.8M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $27.0M +135.3% | $11.5M -25.1% | $15.3M -28.9% | $21.5M -28.6% | $30.1M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $570.0M -11.4% | $643.4M +11.9% | $575.2M +20.2% | $478.6M +31.7% | $363.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$270.4M +8.1% | -$294.2M +7.6% | -$318.4M -0.9% | -$315.6M -2.5% | -$307.9M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$55.9M | $0 +100.0% | -$16.6M -304.1% | -$4.1M +97.2% | -$148.4M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$8.7M +91.4% | -$101.3M | $0 | $0 +100.0% | -$7.4M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $5.8M | $0 -100.0% | $5.6M +139.6% | $2.3M -3.9% | $2.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $3.6M +388.8% | -$1.2M -125.2% | $4.9M -77.4% | $21.7M +436.8% | $4.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$330.6M +16.7% | -$396.7M -22.3% | -$324.5M -9.7% | -$295.6M +35.3% | -$457.2M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $388.6M +498.8% | -$97.5M -89.1% | -$51.6M -1133.5% | $5.0M -86.5% | $37.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $18.9M | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$365.0M -431.8% | -$68.6M -44.3% | -$47.6M +48.4% | -$92.1M -17.9% | -$78.1M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$120.8M -5.9% | -$114.1M -10.0% | -$103.7M -4.2% | -$99.5M -1.0% | -$98.5M | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $54.8M +75.5% | $31.2M +27.5% | $24.5M -57.9% | $58.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$78.3M +65.3% | -$225.3M -31.4% | -$171.6M -5.8% | -$162.1M -98.8% | -$81.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $17.0M +180.3% | -$21.1M -1066.1% | $2.2M +304.2% | -$1.1M +84.1% | -$6.7M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $178.1M +88497.0% | $201.0K -99.8% | $81.4M +311.0% | $19.8M +110.9% | -$182.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $299.6M -14.2% | $349.2M +36.0% | $256.8M +57.6% | $163.0M +193.7% | $55.5M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Globus Medical, Inc.
NYSE:GMED
$10.86B
Molina Healthcare, Inc.
NYSE:MOH
$10.44B
Masimo Corporation
NASDAQ:MASI
$9.42B
Henry Schein, Inc.
NASDAQ:HSIC
$9.31B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.26B
Repligen Corporation
NASDAQ:RGEN
$7.46B
Grifols, S.A.
NASDAQ:GRFS
$6.49B
Avantor, Inc.
NYSE:AVTR
$6.47B
Teleflex Incorporated
NYSE:TFX
$5.78B
Stevanato Group S.p.A.
NYSE:STVN
$4.65B
SEC Filings
Recent regulatory filings
No filings found.
Does ATR generate free cash flow?
AptarGroup, Inc. (ATR) generated $299.58M of free cash flow in fiscal 2025.
How much operating cash flow does ATR produce?
Operating cash flow was $570.00M, before capital expenditures of $270.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.